In 2016, the company achieved strategic transformation, shifting its development direction from localized processing business to international pharmaceutical research and development. Its business market expanded from domestic and Asian, African, and Latin American markets to European and American markets as well as domestic high-end markets

Collaborating with renowned pharmaceutical companies in India to develop over 10 products targeting respiratory system and cardiovascular and cerebrovascular treatments; currently, 6 products under research have been initiated and achieved phased results

Introduce international experts and talents with international work experience, establish international quality management systems, human resource management systems, and EHS systems, implement bilingual office practices, increase communication and learning with foreign partners, and foster a strong international atmosphere.

Kivipharm Co., Ltd has established an overseas company in Hamburg, Germany. Over 20 varieties under research will undergo dual declaration in the European Union and the United States. Among them, minocycline sustained-release tablets have completed BE experiments in Canada, and the solid dosage workshop obtained FDA certification in 2024.